Polypid Ltd (PYPD)

$5.01 +0.28 (5.92%)
Market Cap 90.26M
Revenue (ttm) 0.00
Net Income (ttm) -34.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 156,700
Avg Vol 236,804
Day's Range N/A - N/A
Shares Out 19.08M
Stochastic %K 87%
Beta 1.41
Analysts Strong Sell
Price Target $11.75

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 4719 5700
Address:
18 Hasivim Street, Petah Tikva, Israel
robbied61
robbied61 Aug. 19 at 11:47 PM
$PYPD agreed
0 · Reply
Finnish_boy
Finnish_boy Aug. 19 at 9:04 PM
$PYPD XBI up today +5%.. that's why PYPD up also. Very happy stock back to $5.0.. lets see where SP will be when they submit MAA late next month. I would like to see major PDUFA run up in October-November but time will tell. Imo run up very likely bc market cap only 100M and it should be 300M today. Exciting
0 · Reply
Alberthansson02
Alberthansson02 Aug. 19 at 8:37 PM
$PYPD simply lovely having a day in the Beautiful city of Oslo, and having the most green day of my life
0 · Reply
Loofie
Loofie Aug. 19 at 7:55 PM
$PYPD we broke the 5$ again 😎
0 · Reply
wanderlust222
wanderlust222 Aug. 19 at 7:47 PM
$PYPD Going pretty good for "29 bearish" 🤭
0 · Reply
trader9165
trader9165 Aug. 19 at 7:27 PM
$PYPD Do we gradually move up towards PDUFA date or we keep bouncing?
1 · Reply
TheSuper
TheSuper Aug. 19 at 2:02 PM
$PYPD Final add for now. Will see how $RFL and $SLS pan out before adding more.
1 · Reply
PaulNipkow
PaulNipkow Aug. 19 at 6:32 AM
$CADL $PYPD With interest rates skyrocketing, the Trump administration will hit the debt ceiling sooner than planned—perhaps as early as early 2027. Hopefully, PYPD could have already cleared it by then ; for CADL, this could affect the FDA / BLA timeline in the event of a shutdown.
2 · Reply
BioSpecialOne
BioSpecialOne Aug. 19 at 5:47 AM
$PYPD before opening a position here I’ve created a dilution map. Let me know what you think please.
1 · Reply
TheSuper
TheSuper Aug. 18 at 3:56 PM
$PYPD Added. Not sure why the drop.
0 · Reply
Latest News on PYPD
PolyPid reports Q2 EPS (35c), consensus (38c)

2026-08-17T09:49:24.000Z - 2 days ago

PolyPid reports Q2 EPS (35c), consensus (38c)

PolyPid Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 7 days ago

PolyPid Earnings Call Transcript: Q2 2026

PolyPid Earnings release: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 7 days ago

PolyPid Earnings release: Q2 2026

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Aug 12, 2026, 7:30 AM EDT - 7 days ago

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital

2026-07-29T15:30:17.000Z - 21 days ago

PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital

PolyPid announces FDA acceptance of, priority review for D-PLEX100

2026-07-29T13:01:07.000Z - 21 days ago

PolyPid announces FDA acceptance of, priority review for D-PLEX100

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

Jul 29, 2026, 8:30 AM EDT - 21 days ago

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid price target lowered to $12 from $13 at Craig-Hallum

2026-07-22T13:15:29.000Z - 4 weeks ago

PolyPid price target lowered to $12 from $13 at Craig-Hallum

Roth says Azurity deal validates D-PLEX100, sees limited near-term revenue

2026-07-21T19:00:15.000Z - 4 weeks ago

Roth says Azurity deal validates D-PLEX100, sees limited near-term revenue

PolyPid Stock (PYPD) Plummets Despite Deal With Azurity to Tackle Surgical Infections

2026-07-21T12:23:53.000Z - 4 weeks ago

PolyPid Stock (PYPD) Plummets Despite Deal With Azurity to Tackle Surgical Infections

PolyPid enters exclusive pact with Azurity Pharmaceuticals for D-PLEX100

2026-07-21T11:40:15.000Z - 4 weeks ago

PolyPid enters exclusive pact with Azurity Pharmaceuticals for D-PLEX100

PolyPid, Azurity sign surgical site infection drug deal

Jul 21, 2026, 7:31 AM EDT - 4 weeks ago

PolyPid, Azurity sign surgical site infection drug deal

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

Jul 21, 2026, 7:30 AM EDT - 4 weeks ago

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid completes NDA submission to FDA for D-PLEX100

2026-06-01T14:27:56.000Z - 2 months ago

PolyPid completes NDA submission to FDA for D-PLEX100

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Jun 1, 2026, 8:30 AM EDT - 2 months ago

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference

May 28, 2026, 11:30 AM EDT - 2 months ago

PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

May 20, 2026, 8:30 AM EDT - 3 months ago

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid reports Q1 EPS (35c), consensus (43c)

2026-05-13T17:09:41.000Z - 3 months ago

PolyPid reports Q1 EPS (35c), consensus (43c)

PolyPid Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

PolyPid Earnings Call Transcript: Q1 2026

PolyPid Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

PolyPid Earnings release: Q1 2026

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 13, 2026, 7:30 AM EDT - 3 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Apr 28, 2026, 8:30 AM EDT - 4 months ago

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Apr 13, 2026, 9:15 AM EDT - 4 months ago

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

Mar 31, 2026, 8:30 AM EDT - 5 months ago

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid granted $4.3M waiver from FDA for D-Plex application

2026-03-17T12:46:11.000Z - 5 months ago

PolyPid granted $4.3M waiver from FDA for D-Plex application

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Mar 17, 2026, 8:30 AM EDT - 5 months ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:40 PM EDT - 5 months ago

PolyPid Transcript: The Citizens Life Sciences Conference 2026

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 25, 2026, 8:35 AM EST - 6 months ago

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Earnings Call Transcript: Q4 2025

Feb 11, 2026, 8:30 AM EST - 6 months ago

PolyPid Earnings Call Transcript: Q4 2025

PolyPid Annual report: Q4 2025

Feb 11, 2026, 8:30 AM EST - 6 months ago

PolyPid Annual report: Q4 2025

PolyPid Earnings release: Q4 2025

Feb 11, 2026, 8:30 AM EST - 6 months ago

PolyPid Earnings release: Q4 2025

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 7:30 AM EST - 6 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid Slides: Investor presentation

Feb 11, 2026, 6:00 AM EST - 6 months ago

PolyPid Slides: Investor presentation

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Jan 28, 2026, 8:00 AM EST - 7 months ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 10:30 AM EST - 7 months ago

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

PolyPid appoints Story as Chairman of Board of Directors

2025-12-16T13:41:48.000Z - 8 months ago

PolyPid appoints Story as Chairman of Board of Directors

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 16, 2025, 8:30 AM EST - 8 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid Transcript: KOL Event

Dec 10, 2025, 11:30 AM EST - 9 months ago

PolyPid Transcript: KOL Event

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

2025-12-03T13:35:51.000Z - 9 months ago

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Dec 3, 2025, 8:30 AM EST - 9 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 25, 2025, 8:30 AM EST - 9 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

PolyPid Slides: Corporate Presentation

Nov 18, 2025, 7:00 AM EST - 9 months ago

PolyPid Slides: Corporate Presentation

PolyPid price target lowered to $9 from $10 at Roth Capital

2025-11-13T11:16:03.000Z - 9 months ago

PolyPid price target lowered to $9 from $10 at Roth Capital

PolyPid Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

PolyPid Earnings Call Transcript: Q3 2025

PolyPid Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

PolyPid Earnings release: Q3 2025

PolyPid sees cash runway ‘well into’ 2026

2025-11-12T12:41:32.000Z - 10 months ago

PolyPid sees cash runway ‘well into’ 2026

PolyPid reports Q3 EPS (37c), consensus (52c)

2025-11-12T12:35:15.000Z - 10 months ago

PolyPid reports Q3 EPS (37c), consensus (52c)

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:30 AM EST - 10 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Nov 6, 2025, 8:30 AM EST - 10 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Oct 29, 2025, 8:30 AM EDT - 10 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 12:30 PM EDT - 11 months ago

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 30, 2025, 8:45 AM EDT - 11 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 8:44 AM EDT - 1 year ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid completes Israeli Ministry of Health GMP inspection

2025-09-16T12:45:43.000Z - 1 year ago

PolyPid completes Israeli Ministry of Health GMP inspection

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 16, 2025, 8:30 AM EDT - 1 year ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 1 year ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Sep 2, 2025, 8:30 AM EDT - 1 year ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid price target lowered to $13 from $15 at Craig-Hallum

2025-08-14T13:30:37.000Z - 1 year ago

PolyPid price target lowered to $13 from $15 at Craig-Hallum

PolyPid price target raised to $10 from $9 at Roth Capital

2025-08-14T12:05:26.000Z - 1 year ago

PolyPid price target raised to $10 from $9 at Roth Capital

PolyPid Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q2 2025

PolyPid Earnings release: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings release: Q2 2025

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:30 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 1 year ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PolyPid Registration statement: Registration Filing

Jul 29, 2025, 8:00 AM EDT - 1 year ago

PolyPid Registration statement: Registration Filing

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jul 15, 2025, 8:00 AM EDT - 1 year ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 16, 2025, 7:20 PM EDT - 1 year ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PolyPid Slides: Corporate Presentation

Jun 12, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Corporate Presentation

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:42 AM EDT - 1 year ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 1 year ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:54 AM EDT - 1 year ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PolyPid Transcript: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Transcript: Status Update

PolyPid Press release: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Press release: Status Update

PolyPid Slides: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Slides: Status Update

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:30 AM EDT - 1 year ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid Slides: Investor Presentation

Jun 9, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Investor Presentation

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Jun 6, 2025, 4:05 PM EDT - 1 year ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 30, 2025, 10:12 AM EDT - 1 year ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

May 29, 2025, 10:15 AM EDT - 1 year ago

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 20, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q1 2025

PolyPid Earnings release: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings release: Q1 2025

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

Apr 22, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 11:20 AM EST - 1 year ago

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

PolyPid Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q4 2024

PolyPid Annual report: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Annual report: Q4 2024

PolyPid Earnings release: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings release: Q4 2024

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PolyPid Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

PolyPid Registration statement: Registration Filing

PolyPid Slides: Corporate Presentation

Jan 14, 2025, 6:00 PM EST - 1 year ago

PolyPid Slides: Corporate Presentation

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

robbied61
robbied61 Aug. 19 at 11:47 PM
$PYPD agreed
0 · Reply
Finnish_boy
Finnish_boy Aug. 19 at 9:04 PM
$PYPD XBI up today +5%.. that's why PYPD up also. Very happy stock back to $5.0.. lets see where SP will be when they submit MAA late next month. I would like to see major PDUFA run up in October-November but time will tell. Imo run up very likely bc market cap only 100M and it should be 300M today. Exciting
0 · Reply
Alberthansson02
Alberthansson02 Aug. 19 at 8:37 PM
$PYPD simply lovely having a day in the Beautiful city of Oslo, and having the most green day of my life
0 · Reply
Loofie
Loofie Aug. 19 at 7:55 PM
$PYPD we broke the 5$ again 😎
0 · Reply
wanderlust222
wanderlust222 Aug. 19 at 7:47 PM
$PYPD Going pretty good for "29 bearish" 🤭
0 · Reply
trader9165
trader9165 Aug. 19 at 7:27 PM
$PYPD Do we gradually move up towards PDUFA date or we keep bouncing?
1 · Reply
TheSuper
TheSuper Aug. 19 at 2:02 PM
$PYPD Final add for now. Will see how $RFL and $SLS pan out before adding more.
1 · Reply
PaulNipkow
PaulNipkow Aug. 19 at 6:32 AM
$CADL $PYPD With interest rates skyrocketing, the Trump administration will hit the debt ceiling sooner than planned—perhaps as early as early 2027. Hopefully, PYPD could have already cleared it by then ; for CADL, this could affect the FDA / BLA timeline in the event of a shutdown.
2 · Reply
BioSpecialOne
BioSpecialOne Aug. 19 at 5:47 AM
$PYPD before opening a position here I’ve created a dilution map. Let me know what you think please.
1 · Reply
TheSuper
TheSuper Aug. 18 at 3:56 PM
$PYPD Added. Not sure why the drop.
0 · Reply
smile696
smile696 Aug. 18 at 3:54 PM
$PYPD Just added another 1000
0 · Reply
TomiGurArie
TomiGurArie Aug. 18 at 10:16 AM
$PYPD my only question here, who are the sellers?
0 · Reply
PaulNipkow
PaulNipkow Aug. 18 at 7:37 AM
$PYPD try to use https://483signal.com/ Instead of waiting for a 483 to be prublished, track the FOIA Submission Log - but in general no News = Good News (the opposite Bad news need a 8K within 4 days)
0 · Reply
TheSuper
TheSuper Aug. 17 at 7:59 PM
$PYPD Added a decent amount today.. Have a little more to put at this tomorrow.
0 · Reply
TheSuper
TheSuper Aug. 17 at 7:56 PM
$PYPD Its 10% odds for a CRL but only 6% odds if you look at just manufacturing issues. 4% falls into buckets we likly are derisked on.
0 · Reply
robbied61
robbied61 Aug. 17 at 12:39 PM
$PYPD finish i have an important ?for you. If company gets manufacturing facility approved can they make that public, next if that gets approved i believe risk is all but gone. Last there approval date is 11. 28. Which is thanks giving weekend is there a 7 person panel meeting for approval
0 · Reply
Finnish_boy
Finnish_boy Aug. 17 at 9:17 AM
$PYPD Yes. Stock can be flat until 28th November and then CRL (10% odds) and stock crashes -50%.. remember risks.. this is biotech.
1 · Reply
robbied61
robbied61 Aug. 16 at 10:37 PM
$PYPD finish i am not sure what moves the needle ilike u now this is under valued. How ever i believe more miestones and manufacturing facility being approved has to nove the needle would be happy 9 or 10 ashare final approval and final milestones on. Nov 28th
0 · Reply
Finnish_boy
Finnish_boy Aug. 15 at 10:25 PM
$PYPD My near-term setup failed. Mid-term/ long-term valid.
0 · Reply
Finnish_boy
Finnish_boy Aug. 15 at 10:19 PM
$PYPD This is now just waiting game. I will be back when they press release MAA submission late September. Lets watch where share price will be at that moment.
0 · Reply
robbied61
robbied61 Aug. 15 at 7:08 PM
$PYPD oh well sour grapes 🍇
0 · Reply
robbied61
robbied61 Aug. 15 at 7:08 PM
$PYPD we definitely make mony what erks me is the lack of any credibility based on price that the street wont give pypd
0 · Reply